このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Exact Sciences 将来の成長

Future 基準チェック /46

Exact Sciences利益と収益がそれぞれ年間65.2%と11.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に5.7% 66.2%なると予測されています。

主要情報

65.9%

収益成長率

66.8%

EPS成長率

Biotechs 収益成長	24.6%
収益成長率	11.2%
将来の株主資本利益率	5.7%
アナリストカバレッジ	Good
最終更新日	05 Jun 2024

今後の成長に関する最新情報

Recent updates

Exact Sciences: Still No Reason To Own

Jun 11

Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

Jun 02

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Feb 23

Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Jan 08

Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Nov 15

Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

Oct 04

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Aug 14

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued

Jan 10

Would Exact Sciences (NASDAQ:EXAS) Be Better Off With Less Debt?

Oct 31

Exact Sciences: Price Is Yet To Catch Up As Management Draws Profitability Plans

Oct 13

Exact Sciences: Negative EPS And Free Cash Flow, More Downside Likely

Aug 15

業績と収益の成長予測

NasdaqCM:EXAS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	3,616	106	536	632	14
12/31/2025	3,219	-38	336	422	21
12/31/2024	2,831	-203	25	167	21
3/31/2024	2,535	-240	-20	112	N/A
12/31/2023	2,500	-204	32	156	N/A
9/30/2023	2,406	-282	-24	139	N/A
6/30/2023	2,301	-432	-108	73	N/A
3/31/2023	2,200	-517	-298	-88	N/A
12/31/2022	2,084	-624	-438	-224	N/A
9/30/2022	2,005	-716	-443	-300	N/A
6/30/2022	1,938	-735	-437	-300	N/A
3/31/2022	1,852	-745	-330	-199	N/A
12/31/2021	1,767	-596	-238	-102	N/A
9/30/2021	1,760	-793	-117	34	N/A
6/30/2021	1,712	-829	30	156	N/A
3/31/2021	1,546	-720	19	109	N/A
12/31/2020	1,491	-824	71	136	N/A
9/30/2020	1,321	-327	-89	0	N/A
6/30/2020	1,131	-165	-238	-111	N/A
3/31/2020	1,062	-136	-262	-87	N/A
12/31/2019	876	-213	-284	-112	N/A
9/30/2019	724	-216	-271	-88	N/A
6/30/2019	623	-221	-248	-62	N/A
3/31/2019	526	-219	-250	-105	N/A
12/31/2018	454	-175	-219	-69	N/A
9/30/2018	399	-143	-203	-69	N/A
6/30/2018	353	-124	-167	-70	N/A
3/31/2018	308	-119	-158	-77	N/A
12/31/2017	266	-114	N/A	-72	N/A
9/30/2017	214	-130	N/A	-98	N/A
6/30/2017	169	-141	N/A	-118	N/A
3/31/2017	133	-155	N/A	-121	N/A
12/31/2016	99	-167	N/A	-130	N/A
9/30/2016	79	-170	N/A	-133	N/A
6/30/2016	63	-175	N/A	-145	N/A
3/31/2016	50	-169	N/A	-141	N/A
12/31/2015	39	-158	N/A	-134	N/A
9/30/2015	27	-150	N/A	-135	N/A
6/30/2015	14	-139	N/A	-119	N/A
3/31/2015	6	-120	N/A	-104	N/A
12/31/2014	2	-100	N/A	-81	N/A
9/30/2014	1	-80	N/A	-60	N/A
6/30/2014	2	-59	N/A	-46	N/A
3/31/2014	3	-52	N/A	-40	N/A
12/31/2013	4	-47	N/A	-40	N/A
9/30/2013	4	-48	N/A	-40	N/A
6/30/2013	4	-50	N/A	-43	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EXASは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: EXAS今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: EXAS今後 3 年以内に収益を上げることが予想されます。

収益対市場: EXASの収益 ( 11.2% ) US市場 ( 8.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: EXASの収益 ( 11.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EXASの自己資本利益率は、3年後には低くなると予測されています ( 5.7 %)。

Exact Sciences 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 19%

Forecast breakeven date pushed back to 2026

Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024

Consensus EPS estimates upgraded to US$0.89 loss

Forecast breakeven date moved forward to 2025

Exact Sciences Corporation Provides Revenue Guidance for the Year 2024

Recent updates

Exact Sciences: Still No Reason To Own

Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations At Asco®

Consensus EPS estimates fall by 19%

New minor risk - Shareholder dilution

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024

Exact Sciences Corporation, Annual General Meeting, Jun 13, 2024

New minor risk - Shareholder dilution

Exact Sciences Corporation announced that it has received $266.75 million in funding

Exact Sciences Corporation Announces Executive Changes

Exact Sciences Corporation announced that it expects to receive $266.8 million in funding

Exact Sciences Corporation to Report Q1, 2024 Results on May 08, 2024

Exact Sciences Corp. Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Consensus EPS estimates upgraded to US$0.89 loss

Forecast breakeven date moved forward to 2025

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Full year 2023 earnings: EPS exceeds analyst expectations

Exact Sciences Corporation Provides Revenue Guidance for the Year 2024

Chairman of The Board & CEO notifies of intention to sell stock

Exact Sciences Corporation to Report Q4, 2023 Results on Feb 21, 2024

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024

Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Executive Vice President

Forecast to breakeven in 2026

Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

No longer forecast to breakeven

Third quarter 2023 earnings released: EPS: US$0.004 (vs US$0.84 loss in 3Q 2022)

Price target decreased by 9.3% to US$97.41

Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023

Forecast to breakeven in 2025

Exact Sciences Corp. Announces Late-Breaking Data from the Pivotal Blue-C Trial

Chief Commercial Officer notifies of intention to sell stock

No longer forecast to breakeven

Exact Sciences Corporation to Report Q3, 2023 Results on Nov 01, 2023

Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

Price target increased by 7.0% to US$109

Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A).

Executive VP & CFO notifies of intention to sell stock

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Consensus estimates of losses per share improve by 11%

Exact Sciences Corporation Announces Impairment of Long-Lived Assets for the Second Quarter Ended June 30, 2023

New minor risk - Shareholder dilution

Forecast to breakeven in 2025

Now 20% undervalued

Exact Sciences Corporation to Report Q2, 2023 Results on Aug 01, 2023

Exact Sciences Corporation to Report Q2, 2023 Results on Aug 01, 2023

Now 21% undervalued

Price target increased by 14% to US$98.23

Exact Sciences Corp. Announces Positive Top-Line Results from the Pivotal Blue-C Study

Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Lead Independent Director notifies of intention to sell stock

Exact Sciences Corp. Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO 2023

Consensus estimates of losses per share improve by 19%

Price target increased by 8.7% to US$80.96

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus Cloud Solutions, Inc. Revises Earnings Guidance for the Year 2023

Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

Insider notifies of intention to sell stock

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Price target increased by 11% to US$70.53

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Executive VP exercised options and sold US$75k worth of stock

Insider notifies of intention to sell stock

Exact Sciences Corporation to Report Q4, 2022 Results on Feb 21, 2023

Lead Independent Director exercised options to buy US$363k worth of stock.